Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/57763
Título
Clinical perspective and translational oncology of liquid biopsy
Autor
Año del Documento
2020
Editorial
MDPI
Descripción
Producción Científica
Documento Fuente
Diagnostics, 2020, Vol. 10, Nº. 7, 443
Resumen
The term liquid biopsy (LB) refers to the study of circulating tumor cells, circulating tumors nucleic acids free of cells or contained in exosomes, and information about platelets associated with tumors. LB can be performed in different biofluids and allows the limitations of tissue biopsy to be overcome offering possibilities of tumor identification reflecting in real time tumor heterogeneity. In addition, LB allows screening and early detection of cancer, real-time monitoring of therapy, stratification and therapeutic intervention, a therapeutic target and resistance mechanism, and a risk of metastatic relapse. Currently, LB has been shown to be effective for its application in different types of tumors including lung, colorectal, prostate, melanoma, breast and pancreatic cancer, by the determination and identification of biomarkers that with a high probability have the potential to change the way in which medical oncology could predict the course of the disease. These biomarkers make it possible to capture the heterogeneity of the cancer, monitor its clonal evolution, indicate new treatments or retreatments and evaluate the responses to different evolutionary and/or therapeutic pressures in the cancer disease.
Materias (normalizadas)
Cancer research
Cancer - Early detection
Cancer - Molecular aspects
Liquid Biopsy
General practice (Medicine)
Translational Medical Research
Materias Unesco
3207.13 Oncología
ISSN
2075-4418
Revisión por pares
SI
Version del Editor
Propietario de los Derechos
© 2020 The Author(s)
Idioma
eng
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Aparece en las colecciones
Ficheros en el ítem
Tamaño:
1.098Mb
Formato:
Adobe PDF
La licencia del ítem se describe como Atribución 4.0 Internacional